• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人源及重组血管性血友病因子多聚化对血小板聚集、与胶原蛋白结合及凝血因子 VIII 结合的影响。

Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII.

作者信息

Fischer B E, Kramer G, Mitterer A, Grillberger L, Reiter M, Mundt W, Dorner F, Eibl J

机构信息

IMMUNO AG, Biomedical Research Center, Orth/Donau, Austria.

出版信息

Thromb Res. 1996 Oct 1;84(1):55-66. doi: 10.1016/0049-3848(96)00161-2.

DOI:10.1016/0049-3848(96)00161-2
PMID:8885147
Abstract

The smallest circulating von Willebrand factor (vWF) molecule is a dimer composed of two identical subunits containing binding sites for heparin, collagen, platelet glycoproteins and coagulation factor VIII (FVIII). Interdimeric disulfide linking leads to multimers composed of up to 40 dimers. vWF serves as a carrier of FVIII and is required for normal interactions of platelets with the subendothelium of the injured vessel wall. Von Willebrand factor was purified from human plasma cryoprecipitate and fermentation supernatant of recombinant CHO cells by anion exchange chromatography. Heparin affinity chromatography was used to isolate vWF polymers of different degree of multimerization. Analysis of collagen binding and platelet aggregation revealed that these activities increase with increasing degree of multimerization of vWF. Binding of FVIII to vWF was studied by real-time biospecific interaction analysis and surface plasmon technology. The binding data showed that the binding of FVIII is independent of vWF multimerization. Using recombinant FVIII and recombinant vWF, real-time biospecific interaction analysis resulted in a potential stoichiometry of 2 to 2.5 vWF-subunits per bound FVIII molecule. The kinetic analysis of the vWF-FVIII interaction resulted in a binding rate constant of about 3 x 10(6) M-1 s-1 and an equilibrium dissociation constant of about 0.4 x 10(-9) M.

摘要

循环中的最小血管性血友病因子(vWF)分子是一种二聚体,由两个相同的亚基组成,这些亚基含有肝素、胶原蛋白、血小板糖蛋白和凝血因子VIII(FVIII)的结合位点。二聚体间的二硫键连接导致形成由多达40个二聚体组成的多聚体。vWF作为FVIII的载体,是血小板与受损血管壁内皮下层正常相互作用所必需的。血管性血友病因子是通过阴离子交换色谱法从人血浆冷沉淀物和重组CHO细胞的发酵上清液中纯化得到的。肝素亲和色谱法用于分离不同多聚化程度的vWF聚合物。胶原蛋白结合分析和血小板聚集分析表明,这些活性随着vWF多聚化程度的增加而增强。通过实时生物特异性相互作用分析和表面等离子体技术研究了FVIII与vWF的结合。结合数据表明,FVIII的结合与vWF的多聚化无关。使用重组FVIII和重组vWF进行实时生物特异性相互作用分析,结果显示每个结合的FVIII分子的潜在化学计量比为2至2.5个vWF亚基。vWF - FVIII相互作用的动力学分析得出结合速率常数约为3×10⁶ M⁻¹ s⁻¹,平衡解离常数约为0.4×10⁻⁹ M。

相似文献

1
Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII.人源及重组血管性血友病因子多聚化对血小板聚集、与胶原蛋白结合及凝血因子 VIII 结合的影响。
Thromb Res. 1996 Oct 1;84(1):55-66. doi: 10.1016/0049-3848(96)00161-2.
2
Biochemical and functional characterization of recombinant von Willebrand factor produced on a large scale.大规模生产的重组血管性血友病因子的生化及功能特性
Cell Mol Life Sci. 1997 Dec;53(11-12):943-50. doi: 10.1007/s000180050115.
3
Characterization of 25 monoclonal antibodies to factor VIII-von Willebrand factor: relationship between ristocetin-induced platelet aggregation and platelet adherence to subendothelium.针对凝血因子VIII-血管性血友病因子的25种单克隆抗体的特性:瑞斯托霉素诱导的血小板聚集与血小板黏附于内皮下之间的关系
Blood. 1984 Jun;63(6):1408-15.
4
The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII.血管性血友病因子多聚体及前肽裂解在凝血因子VIII结合与稳定中的作用
J Biol Chem. 1991 Nov 15;266(32):21948-55.
5
Functional domains on von Willebrand factor. Recognition of discrete tryptic fragments by monoclonal antibodies that inhibit interaction of von Willebrand factor with platelets and with collagen.血管性血友病因子的功能结构域。通过抑制血管性血友病因子与血小板及胶原蛋白相互作用的单克隆抗体识别离散的胰蛋白酶片段。
J Clin Invest. 1984 Sep;74(3):736-44. doi: 10.1172/JCI111489.
6
Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III.凝血因子VIII-血管性血友病因子和纤连蛋白在流动血液中血小板与单体及纤维状I型和III型人胶原蛋白相互作用中的作用。
J Clin Invest. 1985 Feb;75(2):531-40. doi: 10.1172/JCI111729.
7
Isolation of the von Willebrand factor domain interacting with platelet glycoprotein Ib, heparin, and collagen and characterization of its three distinct functional sites.血管性血友病因子与血小板糖蛋白Ib、肝素和胶原相互作用结构域的分离及其三个不同功能位点的表征。
J Biol Chem. 1989 Oct 15;264(29):17361-7.
8
Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium, and high multimers of von Willebrand factor.两种对血管性血友病因子低、中、高多聚体具有不同结合亲和力的血管性血友病因子胶原结合试验的比较。
Semin Thromb Hemost. 2002 Apr;28(2):139-48. doi: 10.1055/s-2002-27816.
9
Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.2型诺曼底隐性血管性血友病:轻度血友病和1型血管性血友病的可变表现。
Acta Haematol. 2009;121(2-3):119-27. doi: 10.1159/000214852. Epub 2009 Jun 8.
10
Effect of deletion of the A1 domain of von Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin.在瑞斯托霉素存在的情况下,血管性血友病因子A1结构域缺失对其与肝素、胶原蛋白及血小板结合的影响。
Eur J Biochem. 1991 Mar 14;196(2):369-75. doi: 10.1111/j.1432-1033.1991.tb15826.x.

引用本文的文献

1
Impact of extracorporeal membrane oxygenation treatments on acquired von Willebrand syndrome in patients with out-of-hospital cardiac arrest: a retrospective observational study.体外膜肺氧合治疗对院外心脏骤停患者获得性血管性血友病综合征的影响:一项回顾性观察研究。
Thromb J. 2024 May 31;22(1):46. doi: 10.1186/s12959-024-00617-4.
2
von Willebrand factor Ristocetin co-factor activity to von Willebrand factor antigen level ratio for diagnosis of acquired von Willebrand syndrome caused by aortic stenosis.血管性血友病因子瑞斯托霉素辅因子活性与血管性血友病因子抗原水平之比用于诊断主动脉瓣狭窄所致获得性血管性血友病综合征
Res Pract Thromb Haemost. 2023 Nov 30;8(1):102284. doi: 10.1016/j.rpth.2023.102284. eCollection 2024 Jan.
3
Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease.
重组与血浆来源的血管性血友病因子的结构与功能及其对血管性血友病多聚体药代动力学的影响
J Blood Med. 2022 Nov 14;13:649-662. doi: 10.2147/JBM.S377126. eCollection 2022.
4
Shrinking Weibel-Palade bodies prevents high platelet recruitment in assays using thrombotic thrombocytopenic purpura plasma.在使用血栓性血小板减少性紫癜血浆的检测中,缩小魏尔-帕拉德小体可防止大量血小板募集。
Res Pract Thromb Haemost. 2021 Dec 7;5(8):e12626. doi: 10.1002/rth2.12626. eCollection 2021 Dec.
5
Blood group type A secretors are associated with a higher risk of COVID-19 cardiovascular disease complications.A血型分泌型人群与新冠心血管疾病并发症的较高风险相关。
EJHaem. 2021 May;2(2):175-187. doi: 10.1002/jha2.180. Epub 2021 Apr 2.
6
Administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant manner.去氨加压素的给药并未以具有临床意义的方式改善凝血因子VIII浓缩剂的药代动力学。
J Clin Transl Res. 2018 Feb 21;3(Suppl 2):351-357. eCollection 2018 Jul 30.
7
The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent and independent manner.内皮凝集素清除受体 CLEC4M 以依赖和不依赖 vWF 的方式结合和内化因子 VIII。
J Thromb Haemost. 2019 Apr;17(4):681-694. doi: 10.1111/jth.14404. Epub 2019 Mar 19.
8
Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study).一种血浆源性血管性血友病因子/凝血因子VIII浓缩物(VONCENTO)用于血管性血友病患者按需治疗和预防性治疗的药代动力学、疗效及安全性(SWIFT-VWD研究)
Blood Coagul Fibrinolysis. 2017 Mar;28(2):152-162. doi: 10.1097/MBC.0000000000000568.
9
Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis.血管性血友病因子多聚体的最新进展:聚焦于高分子量多聚体及其在止血中的作用。
Blood Coagul Fibrinolysis. 2014 Apr;25(3):206-16. doi: 10.1097/MBC.0000000000000065.
10
Intravascular recovery of VWF and FVIII following intraperitoneal injection and differences from intravenous and subcutaneous injection in mice.血管内 VWF 和 FVIII 的恢复情况,以及在小鼠中与静脉内和皮下注射的差异。
Haemophilia. 2012 Jul;18(4):639-46. doi: 10.1111/j.1365-2516.2011.02735.x. Epub 2012 Jan 4.